Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565234 | 1.00 | GRIK1 (0.39) | GRIK1GRIK2POLBEP300CISD1 | |
| SCHEMBL148172 | 1.00 | GRIK1 (0.39) | GRIK1GRIK2POLBEP300CISD1 | |
| SCHEMBL116432 | 0.88 | EP300 (0.47) | GRIK1POLBEP300SLC16A3SLC16A1 | |
| SCHEMBL5037139 | 0.88 | EP300 (0.47) | GRIK1POLBEP300SLC16A3SLC16A1 | |
| SCHEMBL5935303 | 0.88 | EP300 (0.47) | GRIK1POLBEP300SLC16A3SLC16A1 | |
| SCHEMBL447973 | 0.86 | EP300 (0.55) | POLBEP300 | |
| SCHEMBL9361015 | 0.86 | EP300 (0.55) | POLBEP300 | |
| SCHEMBL973729 | 0.84 | EP300 (0.58) | POLBEP300 | |
| SCHEMBL142755 | 0.84 | EP300 (0.58) | POLBEP300 | |
| SCHEMBL1274680 | 0.84 | EP300 (0.58) | POLBEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348344-B2 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20070027191-A1 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0335641-B1 | Organic nonlinear optical substance | TEIJIN LTD (JP) | 1994-01-05 | — | — | EP | disclosed |
| US-5196147-A | Optical crystals | TEIJIN LIMITED (JP) | 1993-03-23 | — | — | US | disclosed |
| EP-0335641-A2 | Organic nonlinear optical substance | TEIJIN LIMITED (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027191-A1 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | CHRM1, CHRNA1, CHRNA9 | GRIK1 344/4885GRIK2 475/4885POLB 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.